A Vertically Integrated Cannabis Company in the Making. Leveraging Quebec’s Market.
This Cannara Biotech Inc. profile is part of a paid investor education campaign.*
Cannara Biotech Inc. (CSE:LOVE,FWB:8CB,OTCQB:LOVFF) is building a vertically-integrated cannabis company focused on cultivating and developing cannabis-infused products at its 625,000-square-foot indoor, multi-purpose cultivation facility – one of the largest in Canada and largest to date in Quebec. Once operational, the facility is expected to contain 500,000 square feet of production space, 100,000 square feet of processing space and is expected to be capable of producing over 100,000 kilograms of cannabis annually.
Through Cannara’s collaborative corridor initiative, the company intends to lease space at the facility to product manufacturers to produce cannabis-infused products and expedite them to the market. Cannara is currently in discussions with partners to produce edibles, pet-products, cosmetics, beverages and other products within the facility when the regulations relating to edibles and beverages come into effect in Canada in the near term.
In addition to their facility in Quebec, Cannara has entered the US hemp and cannabidiol (CBD) market through the e-commerce platform, shopCBD.com, which showcases hemp and CBD manufacturers throughout the US. The site plans to offer tinctures, oils, capsules, body care, vape cartridges and pet-related products to US consumers. shopCBD.com recently closed $8.8 million in financing, showing the interest in the growing hemp and CBD market in the US.
To date, Cannara has developed seven cannabis brands that target cannabis consumers in the recreational, cosmeceutical, edible and beverage sectors. To this aim, the company has signed an LOI with a leading Quebec microbrewery to develop cannabinoid-infused beverages. Their product lines are expected to include flower, oils, vapes, topicals, tinctures, creams, gummies and confectionaries, among others. Cannara has also developed an intellectual property (IP) portfolio that includes 19 filed patents and 40 granted domain names and trademarks.
Cannara’s Company Highlights
- Canadian cannabis sales expected to reach $7.17 billion in 2019.
- Quebec’s recreational cannabis market expected to generate between $420 million and $1 billion in sales in 2019.
- Quebec has the lowest cost per gram and electricity rates in Canada.
- 625,000-square-foot indoor, multi-purpose cultivation facility under construction in Farnham, Quebec.
- Phase one construction fully-funded. Phases two and three to be funded through tenants.
- Construction on Phase Two and Three is anticipated to begin in 2020.
- IP portfolio with 19 filed patents and 40 granted domain names and trademarks.
- Seven brands across medical, recreational, pet care, cosmeceutical, beverage and edible markets.
- Ongoing R&D to develop new products and formulations to address consumer demand.
- Holds a 61 percent interest in US e-commerce platform shopCBD.com.
- shopCBD.com recently closed $8.8 million in financing.
- US hemp-derived CBD market is expected to reach $22 billion by 2022.
The Quebec Advantage
Canadian cannabis sales are expected to generate up to $7.17 billion in sales in 2019. In Quebec alone, the recreational cannabis market is expected to generate between $420 million and $1 billion in sales, making it the second-largest cannabis market in Canada.
When compared to other provinces and territories, Quebec provides cannabis companies with a competitive advantage. To date, Health Canada has issued licenses to only 16 companies in Quebec and the province has expressed an interest in supporting local growers and producers. Additionally, Quebec offers some of the lowest energy costs in the country and a strong pool of land, labor and technical expertise.
Farnham, Quebec Facility
Cannara has secured a 625,000-square-foot facility in Farnham, Quebec, which is 45 minutes away from Montreal. The company has recently submitted its evidence package to Health Canada and expects to receive its cultivation license in the near term.
The indoor, multi-purpose facility is expected to include 500,000 square feet of production space, with capabilities such as cultivation, trimming, curing and extraction, and 100,000 square feet of processing space.
The company is building out the facility in three phases. Phase one construction, which is expected to consist of 170 square feet, is fully-funded and expected to be completed in the near term. Phase Two and Phase Three construction is anticipated to begin in 2020. Until then, Cannara intends to lease 300 square feet to two non-cannabis tenants, which is expected to provide the company with $2 million per year in rental income and covers the carrying cost of the facility.
Once operational, the facility is expected to produce over 100,000 kilograms of cannabis per annum.
Credits: Tour de Force Média
The advantages of indoor growing
Cannara is focused on growing cannabis indoors because it offers numerous advantages over outdoor or greenhouse growing operations. The company believes that growing in a pharma-grade GMP facility offers superior yield and less risk.
Cannara’s Collaborative Corridor
Cannara is in discussions with product manufacturers to form joint-venture partnerships for the development of cannabis products. Its Farnham facility is expected to be used by joint venture partners to produce cannabis-infused products onsite to facilitate manufacturing processes, formulation and speed to market.
FV Pharma Agreement
In April 2018, Cannara and FV Pharma, a subsidiary of FSD Pharma Inc. (CSE:HUGE,OTCQB:FSDDF,FWB:0K9), signed an agreement for FV Pharma to open a second production site at Cannara’s Farnham facility. FV Pharma has applied for a site B license to grow cannabis at the Farnham facility until Cannara receives its cultivation license from Health Canada.
Since legalization in October 2018, the demand for cannabis products has been high, and many companies are looking towards the legalization of cannabis-infused edibles and beverages. In the meantime, Cannara has been curating numerous brands and formulations in preparation for the roll-out of value-added products later this year. To this aim, the company has signed an LOI with a leading Quebec microbrewery to develop cannabinoid-infused beverages.
Cannara is developing seven cannabis brands that target all cannabis consumers across Canada and offer recreational, cosmeceutical, edible and beverage products. The company is also conducting R&D activities targeting a variety of other products and formulations to ensure that its product portfolio and brands appeal to a vast selection of consumers.
Nativa is Cannara’s flower and oils brand for cannabis consumers with a high tolerance. Products under the brand include flower, oil, concentrates, pre-rolls, vapes, vape accessories and cartridges.
Edible and beverage brands
Cannabar is expected to feature a wellness line centered around snacks such as chocolate, granola and protein bars, brownies and cookies, all in snack-sized and regular-sized formats.
Gummyz, as the name suggests, intends to offer consumers cannabis-infused candies, chewables and gummy candies.
Liquid CBD plans to offer a line of CBD-infused water, vitamin water and other hydration beverages. The brand is expected to offer four flavors.
Earth Magic is Cannara’s line of cosmeceutical products. The line is expected to include topicals, lip balms and dermal creams. The company has developed two formulations for their products, one with soothing properties and the other for pain relief.
Floragel is expected to be Cannara’s line of CBD softgels and tinctures for those looking to self-medicate and find relief for anxiety, stress and sleeplessness, among others.
Pet Leaf is to be marketed to pet owners looking to take care of their furry companions with natural ingredients. The product line is expected to include pet treats, wellness oils and other care products.
Entering the US Hemp and CBD Market
In January 2019, Cannara entered the US hemp market through a subsidiary with an e-commerce platform called shopCBD.com. The platform showcases hemp and CBD manufacturers throughout the US. shopCBD.com is expected to offer a variety of products including tinctures, oils, capsules, body care, vape cartridges and pet-related products. shopCBD.com recently closed $8.8 million in financing, showing the interest in the growing hemp and CBD market in the US.
“We are taking a leadership role by creating a hub for vendors to showcase their products and consumers to purchase hemp-CBD products in a fast and easy way. We want to become the Amazon of CBD”, said Krivorot.
With the passing of the 2018 US Farm Bill, CBD has been rising in popularity among cannabis companies and consumers looking for natural-based health and wellness solutions for various ailments. As a result, the US hemp-derived CBD market is expected to reach $22 billion by 2022, according to the Brightfield Group.
Cannara’s Management Team
Zohar Krivorot — CEO and Founder
As a successful entrepreneur, Zohar Krivorot has founded, advised, invested and sold numerous companies, including voice-over IP application platform 911ENABLE™, which he led from start-up to its acquisition by West Telecom in 2014. Krivorot is recognized as a top leader and innovator by a number of sources, including Deloitte Technology Fast 50™ fastest growing technology companies in Canada. He is actively involved with early-stage companies as an advisor and board member.
Lennie Ryer, CPA, CA — CFO
Lennie Ryer was the CFO and Vice-President of Finance at ConjuChem Biotechnologies Inc., a publicly-traded biotechnology company developing peptide-based drugs to improve the treatment of human diseases. He has also worked at Paladin Labs Inc., a specialty pharmaceutical firm, in the position of CFO and VP Finance. At Paladin, Ryer transitioned the company to the TSX and led the company’s most significant financing initiative.
Barry Laxer — COO
Barry is a successful business leader that brings over 25 years of experience of leading large-scale operations both domestically and internationally.
As a business owner, Barry partnered with major global active sportswear brands including Nike, Under Armour, Adidas, Nautica and Puma to meet rigorous demands in terms of delivery quality and product performance on an international level. His specialization also includes helping industry organizations achieve profitability, quality and compliance requirements.
Alex Wolfe – VP Business Development
Alex is a long-standing believer and advocate for legal cannabis. He brings to the team over 10 years of experience in sales and business development within regulated industries and refined from his time in alcohol and liquor sales and marketing.
Before joining Cannara, Alex’s diverse background included Air Canada where he worked in strategic partnership development that led to significant revenue growth for the airline. Alex continues to use his commercial pilot license to help him dart across the globe in the company’s global expansion.
*Disclaimer: The profile provides information which was sourced and approved by Cannara (CSE:LOVE, FRA:8CB, OTCQB:LOVFF) in order to help investors learn more about the company. Cannara is a client of the Investing News Network (INN). The company’s campaign fees pay for INN to create and update this profile page, to which links are placed on Investingnews.com and channel newsletters.
The company description, investment highlights and catalysts were sourced by INN and approved by the company. INN does not guarantee the accuracy or thoroughness of the information contained on this page.
INN does not provide investment advice and the information on Investingnews.com profile should not be considered a recommendation to buy or sell any security.
INN does not endorse or recommend the business, products, services or securities of any company profiled.
Readers should conduct their own research for all information publicly available concerning the company.